Bayer appoints Dr. Juergen Eckhardt as new Head of Pharmaceuticals Business Development & Licensing/Open Innovation

Juergen Eckhardt joined Bayer in 2016 to help start Leaps by Bayer

Former Bayer Pharma CEO Dieter Weinand joins Coya’s Board of Directors

Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business

Bayer partners with biotech firm on lipid nanoparticle delivery systems

Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.

Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData

The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework

CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%

Bayer chronic kidney disease medication Kerendia can gain quick market penetration in India, says GlobalData

Bayer showcases cancer study data at ESMO Congress 2022

On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors

Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke

Bayer’s Vividion emerging as significant player in San Diego Biotech hub

Bayer now present in four of the largest biotechnology hubs in the United States

Bayer posts higher sales, profit in first quarter

Company's net income rose by 57.5 percent to 3.291 billion euros in Q1